Nature's Sunshine Products (NATR) 10-Q 9 Aug 19 2019 Q2 Quarterly report Financial data

Document and Entity Information

Document and Entity Information - shares	6 Months Ended
	Jun. 30, 2019	Aug. 02, 2019
Document and Entity Information
Entity Registrant Name	NATURES SUNSHINE PRODUCTS INC
Entity Central Index Key	0000275053
Document Type	10-Q
Document Period End Date	Jun. 30, 2019
Amendment Flag	false
Current Fiscal Year End Date	--12-31
Entity Current Reporting Status	Yes
Entity Filer Category	Accelerated Filer
Entity Emerging Growth Company	false
Entity Small Business	true
Entity Shell Company	false
Entity Common Stock, Shares Outstanding (in shares)		19,302,281
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q2

CONDENSED CONSOLIDATED BALANCE

CONDENSED CONSOLIDATED BALANCE SHEETS - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Current assets:
Cash and cash equivalents	$ 46,341	$ 50,638
Accounts receivable, net of allowance for doubtful accounts of $454 and $460, respectively	8,727	7,751
Inventories	43,928	42,048
Prepaid expenses and other	6,593	6,388
Total current assets	105,589	106,825
Property, plant and equipment, net	61,911	64,061
Operating lease right-of-use assets	26,361
Investment securities - trading	1,432	1,308
Intangible assets, net	616	618
Deferred income tax assets	8,724	9,056
Other assets	11,618	11,148
Total assets	216,251	193,016
Current liabilities:
Accounts payable	3,998	5,219
Accrued volume incentives and service fees	20,296	20,562
Accrued liabilities	28,077	34,801
Deferred revenue	2,235	1,197
Related party note payable	1,585	1,530
Income taxes payable	2,173	3,378
Current portion of operating lease liabilities	5,241
Total current liabilities	63,605	66,687
Liability related to unrecognized tax benefits	2,157	2,192
Long-term portion of operating lease liabilities	22,418
Deferred compensation payable	1,432	1,308
Long-term deferred income tax liabilities	1,556	1,556
Other liabilities	345	705
Total liabilities	91,513	72,448
Shareholders’ equity:
Common stock, no par value, 50,000 shares authorized, 19,302 and 19,204 shares issued and outstanding, respectively	134,342	133,684
Retained earnings (accumulated deficit)	2,374	(2,072)
Noncontrolling interest (deficit)	(25)	63
Accumulated other comprehensive loss	(11,953)	(11,107)
Total shareholders’ equity	124,738	120,568
Total liabilities and shareholders’ equity	$ 216,251	$ 193,016

CONDENSED CONSOLIDATED BALANC_2

CONDENSED CONSOLIDATED BALANCE SHEETS (Parenthetical) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Statement of Financial Position [Abstract]
Accounts receivable, allowance for doubtful accounts	$ 454	$ 460
Common stock, shares authorized (in shares)	50,000,000	50,000,000
Common stock, shares issued (in shares)	19,302,000	19,204,000
Common stock, shares outstanding (in shares)	19,302,000	19,204,000

CONDENSED CONSOLIDATED STATEMEN

CONDENSED CONSOLIDATED STATEMENTS OF INCOME - USD ($) shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Income Statement [Abstract]
Net sales	$ 90,724	$ 91,266	$ 181,996	$ 178,608
Cost of sales	23,865	24,278	47,294	46,991
Gross profit	66,859	66,988	134,702	131,617
Operating expenses:
Volume incentives	31,302	31,492	62,315	62,854
Selling, general and administrative	31,019	33,310	64,871	65,696
Operating income	4,538	2,186	7,516	3,067
Other income (loss), net	306	(1,807)	258	(1,067)
Income before provision for income taxes	4,844	379	7,774	2,000
Provision for income taxes	2,215	441	3,416	1,729
Net income (loss)	2,629	(62)	4,358	271
Net loss attributable to noncontrolling interests	(60)	(129)	(88)	(294)
Net income attributable to common shareholders	$ 2,689	$ 67	$ 4,446	$ 565
Basic and diluted net income per common share:
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.14	$ 0	$ 0.23	$ 0.03
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.14	$ 0	$ 0.23	$ 0.03
Weighted average basic common shares outstanding (in shares)	19,291	19,105	19,280	19,058
Weighted average diluted common shares outstanding (in shares)	19,602	19,402	19,596	19,408

CONDENSED CONSOLIDATED STATEM_2

CONDENSED CONSOLIDATED STATEMENTS OF COMPREHENSIVE INCOME (LOSS) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Statement of Comprehensive Income [Abstract]
Net income	$ 2,629	$ (62)	$ 4,358	$ 271
Foreign currency translation loss (net of tax)	(530)	(53)	(846)	(266)
Total comprehensive income	$ 2,099	$ (115)	$ 3,512	$ 5

CONDENSED CONSOLIDATED STATEM_3

CONDENSED CONSOLIDATED STATEMENT OF CHANGES IN SHAREHOLDERS' EQUITY - 6 months ended Jun. 30, 2019 - USD ($) $ in Thousands	Total	Common Stock	Retained Earnings (Accumulated Deficit)	Noncontrolling Interest (Deficit)	Accumulated Other Comprehensive Loss
Beginning balance (in shares) at Dec. 31, 2018	19,204,000	19,204,000
Beginning balance at Dec. 31, 2018	$ 120,568	$ 133,684	$ (2,072)	$ 63	$ (11,107)
Increase (Decrease) in Shareholders' Equity
Share-based compensation expense	851	$ 851
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax (in shares)		98,000
Shares issued from the exercise of stock options and vesting of restricted stock units, net of shares exchanged for withholding tax	(193)	$ (193)
Net income (loss)	4,358		4,446	(88)
Other comprehensive loss	$ (846)				(846)
Ending balance (in shares) at Jun. 30, 2019	19,302,000	19,302,000
Ending balance at Jun. 30, 2019	$ 124,738	$ 134,342	$ 2,374	$ (25)	$ (11,953)

CONDENSED CONSOLIDATED STATEM_4

CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS - USD ($) $ in Thousands	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
CASH FLOWS FROM OPERATING ACTIVITIES:
Net income	$ 4,358	$ 271
Adjustments to reconcile net income to net cash (used in) provided by operating activities:
Provision for doubtful accounts	30	255
Depreciation and amortization	4,987	5,012
Non-cash lease expense	2,792	0
Share-based compensation expense	851	1,124
Loss (gain) on sale of property, plant and equipment	3	(2,267)
Deferred income taxes	365	(744)
Purchase of trading investment securities	(57)	(96)
Proceeds from sale of trading investment securities	105	566
Realized and unrealized gains on investments	(173)	(11)
Foreign exchange (gains) losses	(205)	834
Changes in assets and liabilities:
Accounts receivable	(1,035)	369
Inventories	(2,052)	2,317
Prepaid expenses and other current assets	(259)	(1,471)
Other assets	(767)	(164)
Accounts payable	(1,226)	(28)
Accrued volume incentives and service fees	(235)	673
Accrued liabilities	(6,203)	4,762
Deferred revenue	1,039	(1,795)
Lease liabilities	(2,340)
Income taxes payable	(1,207)	197
Liability related to unrecognized tax benefits	(40)	68
Deferred compensation payable	125	(435)
Net cash (used in) provided by operating activities	(1,144)	9,437
CASH FLOWS FROM INVESTING ACTIVITIES:
Purchases of property, plant and equipment	(2,774)	(2,671)
Proceeds from sale of property, plant and equipment	0	2,558
Net cash used in investing activities	(2,774)	(113)
CASH FLOWS FROM FINANCING ACTIVITIES:
Principal payments of revolving credit facility	(547)	(33,483)
Proceeds from revolving credit facility	547	27,512
Proceeds from related party borrowing	0	500
Proceeds from the exercise of stock awards	0	410
Tax benefit from stock awards	(193)	(465)
Net cash used in financing activities	(193)	(5,526)
Effect of exchange rates on cash and cash equivalents	(186)	190
Net (decrease) increase in cash and cash equivalents	(4,297)	3,988
Cash and cash equivalents at the beginning of the period	50,638	42,910
Cash and cash equivalents at the end of the period	46,341	46,898
SUPPLEMENTAL DISCLOSURE OF CASH FLOW INFORMATION:
Cash paid for income taxes, net of refunds	3,895	2,272
Cash paid for interest	$ 63	$ 160

Basis of Presentation

Basis of Presentation	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent distributors who uses the products themselves or resells them to consumers. Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2019 , and for the three and six -month periods ended June 30, 2019 and 2018 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018 . Noncontrolling Interests Noncontrolling interests decreased as a result of the net loss attributable to the noncontrolling interests by $0.1 million and $0.3 million during the six months ended June 30, 2019 and 2018 , respectively. As of June 30, 2019 and December 31, 2018 , noncontrolling deficits were $25,000 and noncontrolling interests were $0.1 million , respectively. Restructuring Related Accruals and Expenses We recorded $0.4 million and $2.0 million of restructuring related expenses during the three and six months ended June 30, 2019 , respectively. We recorded no restructuring related expenses during the three and six months ended June 30, 2018 . Accrued severance and restructuring related costs were $1.0 million and $0.3 million as of June 30, 2019 and December 31, 2018 , respectively. During the second quarter of 2018, we announced the retirement of our Chief Executive Officer. As a result, we recorded $1.5 million of transition-related expenses during the three and six months ended June 30, 2018 . As of June 30, 2019 and December 31, 2018 , accrued transition costs were $0.6 million and $1.0 million , respectively. Recent Accounting Pronouncements We adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842): Accounting for Leases effective January 1, 2019. This update requires that lessees recognize right-of-use assets and lease liabilities that are measured at the present value of the future lease payments at lease commencement date. See Note 8 - Leases for additional disclosure of the adoption of Topic 842. In February 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Effects from Accumulated Other Comprehensive Income. This update allows a reclassification of stranded tax effects, resulting from the Tax Cuts and Jobs Act 2017, from accumulated other comprehensive income to retained earnings. This ASU is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of ASU 2018-02 did not have a material effect on our results of operations, consolidated financial statements and footnote disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. We are evaluating the potential impact of this adoption on our consolidated financial statements.

Inventories

Inventories	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Inventories	Inventories The composition of inventories is as follows (dollar amounts in thousands): June 30, December 31, Raw materials $ 11,605 $ 10,410 Work in progress 1,286 1,524 Finished goods 31,037 30,114 Total inventories $ 43,928 $ 42,048

Investment Securities - Trading

Investment Securities - Trading	6 Months Ended
	Jun. 30, 2019
Investments, Debt and Equity Securities [Abstract]
Investment Securities - Trading	Investment Securities - Trading Our trading securities portfolio totaled $1.4 million at June 30, 2019 , and $1.3 million at December 31, 2018 , and generated gains of $40,000 and $34,000 for the three months ended June 30, 2019 and 2018 , respectively, and $173,000 and $11,000 for the six months ended June 30, 2019 and 2018 , respectively.

Revolving Credit Facility

Revolving Credit Facility	6 Months Ended
	Jun. 30, 2019
Debt Disclosure [Abstract]
Revolving Credit Facility	Revolving Credit Facility On July 11, 2017, we entered into a revolving credit agreement with Bank of America, N.A., with a borrowing limit of $25.0 million , that matures on July 11, 2020 (the “Credit Agreement”). We pay interest on any borrowings under the Credit Agreement at LIBOR plus 1.25 percent ( 3.65 percent and 3.73 percent as of June 30, 2019 and December 31, 2018 ), and an annual commitment fee of 0.2 percent on the unused portion of the commitment. We are required to settle our net borrowings under the Credit Agreement only upon maturity, and as a result, have classified our outstanding borrowings as non-current on our condensed consolidated balance sheet as of June 30, 2019 . At June 30, 2019 , there was no outstanding balance under the Credit Agreement. The Credit Agreement contains customary financial covenants, including financial covenants relating to our solvency, leverage, and minimum EBITDA. In addition, the Credit Agreement restricts certain capital expenditures, lease expenditures, other indebtedness, liens on assets, guarantees, loans and advances, dividends, and merger, consolidation and the transfer of assets except as permitted in the Credit Agreement. The Credit Agreement is collateralized by our manufacturing facility, accounts receivable balance, inventory balance and other assets. As of June 30, 2019 , we were in compliance with the debt covenants set forth in the Credit Agreement.

Net Income Per Share

Net Income Per Share	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Net Income Per Share	Net Income Per Share Basic net income per common share (“Basic EPS”), is computed by dividing net income by the weighted average number of common shares outstanding during the period. Diluted net income per common share (“Diluted EPS”) reflects the potential dilution that could occur if stock options or other contracts to issue common stock were exercised or converted into common stock. The computation of Diluted EPS does not assume exercise or conversion of securities that would have an anti-dilutive effect on net income per common share. Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2019 and 2018 (dollar and share amounts in thousands, except for per share information): Three Months Ended Six Months Ended 2019 2018 2019 2018 Net income attributable to common shareholders $ 2,689 $ 67 $ 4,446 $ 565 Basic weighted average shares outstanding 19,291 19,105 19,280 19,058 Basic earnings per share attributable to common shareholders $ 0.14 $ — $ 0.23 $ 0.03 Diluted shares outstanding: Basic weighted-average shares outstanding 19,291 19,105 19,280 19,058 Stock-based awards 311 297 316 350 Diluted weighted-average shares outstanding 19,602 19,402 19,596 19,408 Diluted earnings per share attributable to common shareholders $ 0.14 $ — $ 0.23 $ 0.03 Dilutive shares excluded from diluted-per-share amounts: Stock options 445 330 445 330 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options 838 1,160 862 1,160 Potentially dilutive shares excluded from diluted-per-share amounts include performance-based options to purchase shares of common stock for which certain earnings metrics have not been achieved. Potentially anti-dilutive shares excluded from diluted-per-share amounts include both non-qualified stock options and unearned performance-based options to purchase shares of common stock with exercise prices greater than the weighted-average share price during the period and shares that would be anti-dilutive to the computation of diluted net income per share for each of the periods presented.

Capital Transactions

Capital Transactions	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Capital Transactions	Capital Transactions Share-Based Compensation During the year ended December 31, 2012, our shareholders adopted and approved the Nature’s Sunshine Products, Inc. 2012 Stock Incentive Plan (the “2012 Incentive Plan”). The 2012 Incentive Plan provides for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. The Compensation Committee of the Board of Directors has authority and discretion to determine the type of award, as well as the amount, terms and conditions of each award under the 2012 Incentive Plan, subject to the limitations of the 2012 Incentive Plan. A total of 1,500,000 shares of our common stock were originally authorized for the granting of awards under the 2012 Incentive Plan. In 2015, our shareholders approved an amendment to the 2012 Incentive Plan, to increase the number of shares of Common Stock reserved for issuance by 1,500,000 shares. The number of shares available for awards, as well as the terms of outstanding awards, are subject to adjustment as provided in the 2012 Incentive Plan for stock splits, stock dividends, recapitalizations and other similar events. We also maintain a stock incentive plan, which was approved by shareholders in 2009 (the “2009 Incentive Plan”). The 2009 Incentive Plan also provided for the grant of incentive stock options, non-statutory stock options, stock appreciation rights, restricted stock, restricted stock units, dividend equivalent rights, performance awards, stock awards and other stock-based awards. Under the 2012 Incentive Plan, any shares subject to award, or awards forfeited or reacquired by the Company issued under the 2009 Incentive Plan are available for award up to a maximum of 400,000 shares. Stock Options Our outstanding stock options include time-based stock options, which vest over differing periods of time ranging from the date of issuance to up to 48 months from the option grant date, and performance-based stock options, which have already vested upon achieving operating income margins of six , eight and ten percent as reported in four of five consecutive quarters over the term of the options. Stock option activity for the six -month period ended June 30, 2019 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2018 1,114 $ 12.23 Granted — — Forfeited or canceled (173 ) 12.76 Exercised (1 ) 2.35 Options outstanding at June 30, 2019 940 12.15 Share-based compensation expense from time-based stock options for the three-month periods ended June 30, 2019 and 2018 , was approximately $0 and $0.1 million , respectively. Share-based compensation expense from time-based stock options for the six -month periods ended June 30, 2019 and 2018 , was approximately $0 and $0.1 million , respectively. As of June 30, 2019 and December 31, 2018 , there was no unrecognized share-based compensation expense related to the grants described above. At June 30, 2019 , the aggregate intrinsic value of outstanding and exercisable stock options to purchase 940,000 shares of common stock was $0.3 million . At December 31, 2018 , the aggregate intrinsic value of outstanding and exercisable options to purchase 1,114,000 shares of common stock was $0.2 million . For the six -month periods ended June 30, 2019 and 2018 , we issued 1,000 and 69,000 shares of common stock upon the exercise of stock options at an average exercise price of $2.35 and $5.11 per share, respectively. The aggregate intrinsic value of options exercised during the six -month periods ended June 30, 2019 and 2018 , was $10,000 and $0.4 million , respectively. For the six -month periods ended June 30, 2019 and 2018 , the Company recognized $3,000 and $0.1 million of tax benefits from the exercise of stock options, respectively. As of June 30, 2019 and December 31, 2018 , we did no t have any unvested performance-based stock options outstanding. Restricted Stock Units Our outstanding restricted stock units (“RSUs”), include time-based RSUs, which vest over differing periods of time ranging from 12 months to up to 36 months from the RSU grant date, as well as performance-based RSUs, which vest upon achieving targets relating to growth, earnings-per-share, and/or stock price levels. RSUs granted to members of the Board of Directors contain a restriction period in which the shares are not issued until two years after vesting. At June 30, 2019 and December 31, 2018 , there were 78,000 and 80,000 vested RSUs, respectively, given to the Board of Directors that had a restriction period. Restricted stock unit activity for the six -month period ended June 30, 2019 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2018 1,058 $ 8.87 Granted 333 7.23 Forfeited (371 ) 9.92 Issued (109 ) 10.69 Restricted Stock Units outstanding at June 30, 2019 911 7.62 During the six -month period ended June 30, 2019 , we granted 333,000 RSUs under the 2012 Incentive Plan to the Board of Directors, executive officers and other employees, which were comprised of both time-based RSUs and share-priced performance-based RSUs. The time-based RSUs were issued with a weighted-average grant date fair value of $8.59 per share and vest in annual installments over a three -year period from the grant date or according to the restrictions for the Board of Directors noted above. The share-priced performance-based RSUs were issued with a weighted-average grant date fair value of $4.38 per share and vest upon achieving share-priced targets over a three -year period from the grant date. Except for share-priced performance RSUs, RSUs are valued at market value on the date of grant, which is the grant date share price discounted for expected dividend payments during the vesting period. For RSUs with post-vesting restrictions, a Finnerty Model was utilized to calculate a valuation discount from the market value of common shares reflecting the restriction embedded in the RSUs preventing the sale of the underlying shares over a certain period of time. Using assumptions previously determined for the application of the option pricing model at the valuation date, the Finnerty Model discount for lack of marketability is approximately 13.4 percent for a common share. Share-price performance-based RSUs were estimated using the Monte Carlo simulation model. The Monte Carlo simulation model utilizes multiple input variables to estimate the probability that market conditions will be achieved. Our assumptions include a performance period of three years , expected volatility of 50 percent , and a range of risk free rates between 2.1 percent and 2.9 percent . Share-based compensation expense for RSUs for the three-month periods ended June 30, 2019 and 2018 , was approximately $0.5 million and $0.5 million , respectively. Share-based compensation expense from RSUs for the six -month periods ended June 30, 2019 and 2018 , was approximately $0.6 million and $1.0 million , respectively. As of June 30, 2019 and December 31, 2018 , the unrecognized share-based compensation expense related to the grants described above, excluding incentive awards discussed below, was $2.1 million and $1.8 million , respectively. The remaining compensation expense is expected to be recognized over the weighted average period of approximately 0.9 years . Share-based compensation expense related to performance-based RSUs for the three-month periods ended June 30, 2019 and 2018 , was $0.1 million and $0 , respectively. Share-based compensation expense related to performance-based RSUs for the six -month periods ended June 30, 2019 and 2018 , was $0.2 million and $0 , respectively. Should we attain all of the metrics related to performance-based RSU grants, we would recognize up to $2.1 million of potential share-based compensation expense. We currently expect to recognize an additional $1.1 million of that potential share-based compensation expense. The number of shares issued upon vesting of RSUs granted pursuant to our share-based compensation plans is net of the minimum statutory withholding requirements that we pay on behalf of our employees, which was 23,000 and 40,000 shares for the six -month periods ended June 30, 2019 and 2018 , respectively. Although shares withheld are not issued, they are treated as common share repurchases for accounting purposes, as they reduce the number of shares that would have been issued upon vesting. These shares do not count against the authorized capacity under the repurchase program described above.

Segment Information

Segment Information	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Segment Information	Segment Information We have four business segments (Asia, Europe, North America and Latin America and Other) based primarily upon the geographic region where each segment operates, as well as the internal organization of our officers and their responsibilities. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. The Latin America and Other segment includes our wholesale business in which we sell products to various locally-managed entities independent of the Company that we have granted distribution rights for the relevant market. Historically, our operating segments were based on brand, customer base, geographical operations with three operating business segments under the Nature’s Sunshine Products brand (NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China), and one operating business segment under the Synergy® WorldWide brand. During the second quarter of 2019, we realigned into geographic focused operating business segments across brands to further align regional strategies and drive synergies in product, organizational and go-to-market strategies in local markets. Our internal reporting structure was reorganized to support the new reporting segments and the chief operating decision maker now reviews the operating results of the four segments utilizing a geographic focused format. The presentation of the comparative information has been recast to conform to the 2019 presentation. Net sales for each segment have been reduced by intercompany sales as they are not included in the measure of segment profit or loss reviewed by the chief executive officer. We evaluate performance based on contribution margin (loss) by segment before consideration of certain inter-segment transfers and expenses. Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Net sales: Asia $ 35,162 $ 35,767 $ 68,758 $ 63,530 Europe 15,075 13,922 30,672 28,525 North America 34,620 35,518 71,143 73,623 Latin America and Other 5,867 6,059 11,423 12,930 Total net sales 90,724 91,266 181,996 178,608 Contribution margin (1): Asia 16,291 17,275 32,402 29,641 Europe 4,822 4,648 9,827 9,709 North America 12,026 11,180 25,418 24,592 Latin America and Other 2,418 2,393 4,740 4,821 Total contribution margin 35,557 35,496 72,387 68,763 Selling, general and administrative expenses (2) 31,019 33,310 64,871 65,696 Operating income 4,538 2,186 7,516 3,067 Other income (loss), net 306 (1,807 ) 258 (1,067 ) Income before provision for income taxes $ 4,844 $ 379 $ 7,774 $ 2,000 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in China totaled $2.3 million and $4.5 million for the three and six -month periods ended June 30, 2019 , respectively, compared to $2.5 million and $4.0 million for the three and six -month periods ended June 30, 2018 . These service fees are included in selling, general and administrative expenses. From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and six -month periods ended June 30, 2019 and 2018 , as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Net sales: United States $ 32,194 $ 32,914 $ 66,155 $ 68,140 South Korea 18,923 19,608 37,451 34,192 Other 39,607 38,744 78,390 76,276 $ 90,724 $ 91,266 $ 181,996 $ 178,608 Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Asia General health $ 10,752 $ 8,519 $ 18,836 $ 14,753 Immune 199 133 357 434 Cardiovascular 11,561 13,496 23,394 23,398 Digestive 7,333 6,274 12,108 11,698 Personal care 1,820 3,086 6,087 5,268 Weight management 3,497 4,259 7,976 7,979 35,162 35,767 68,758 63,530 Europe General health $ 5,372 $ 5,424 $ 11,120 $ 10,928 Immune 1,090 832 2,363 1,776 Cardiovascular 2,766 2,806 5,617 5,863 Digestive 3,550 3,134 7,181 6,362 Personal care 1,661 1,048 3,160 2,211 Weight management 636 678 1,231 1,385 15,075 13,922 30,672 28,525 North America General health $ 14,934 $ 15,731 $ 30,682 $ 31,830 Immune 3,340 3,344 7,558 8,279 Cardiovascular 4,935 4,870 10,011 9,671 Digestive 8,523 8,521 17,244 17,497 Personal care 1,598 1,268 2,946 2,843 Weight management 1,290 1,784 2,702 3,503 34,620 35,518 71,143 73,623 Latin America and Other General health $ 1,783 $ 1,794 $ 3,395 $ 3,878 Immune 602 567 1,210 1,267 Cardiovascular 361 288 700 766 Digestive 2,645 2,931 5,181 5,883 Personal care 260 302 517 613 Weight management 216 177 420 523 5,867 6,059 11,423 12,930 $ 90,724 $ 91,266 $ 181,996 $ 178,608 From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): June 30, December 31, Property, plant and equipment: United States $ 57,608 $ 60,606 Other 4,303 3,455 Total property, plant and equipment $ 61,911 $ 64,061 Total assets per segment is set forth below (dollar amounts in thousands): June 30, December 31, Assets: Asia $ 72,752 $ 59,983 Europe 17,683 16,414 North America 117,182 109,091 Latin America and Other 8,634 7,528 Total assets $ 216,251 $ 193,016

Leases

Leases	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Leases	Leases Adoption of ASU Topic 842 We adopted ASU No. 2016-02, Leases (Topic 842): Accounting for Leases, as of January 1, 2019. This update requires lessees to recognize right-of-use assets and lease liabilities arising from leases. We elected certain practical expedients permitted under the transition guidance. We elected the optional transition method that allows for a cumulative-effect adjustment and will not restate prior periods. Under the new guidance, all leases will continue to be classified as operating. Adoption of the new standard resulted in recording of additional net operating lease right-of-use assets and lease liabilities of approximately $23.1 million and $24.0 million , respectively, as of January 1, 2019. The difference between the operating lease right-of-use assets and lease liabilities reflects deferred rent balances at the time of adoption. The standard did not materially impact consolidated net earnings and cash flows. We lease certain retail stores, warehouses, distribution centers, and office spaces. Leases with an initial term of 12 months or less are not recorded on the balance sheet; we recognize lease expense for these leases on a straight-line basis over the lease term. For leases beginning in 2019 and later, we account for lease components including rent, real estate taxes and insurance costs separately from non-lease components like common-area maintenance fees. Most of our leases include one or more options to renew, with renewal terms that can extend the lease term for one or more years. The exercise of the lease option to renew is solely at our discretion. Operating lease right-of-use assets and lease liabilities are as follows (dollar amounts in thousands): June 30, January 1, Assets: Operating lease right-of-use assets $ 26,361 $ 23,143 Liabilities: Current $ 5,241 $ 4,426 Long-term 22,418 19,566 Total operating lease liabilities $ 27,659 $ 23,992 Operating lease costs were approximately $1.7 million for the three-months ended June 30, 2019 . Short-term lease costs were approximately $45,000 for the three-months ended June 30, 2019 . Operating lease costs were approximately $3.4 million for the six-months ended June 30, 2019 . Short-term lease costs were approximately $0.1 million for the six-months ended June 30, 2019 . Short-term lease costs represent our costs with respect to leases with a duration of 12 months or less and are not reflected on our Condensed Consolidated Balance Sheets. Supplemental cash flow information related to operating leases for the six-months ended June 30, 2019 was as follows: • Payments of $2.9 million against amounts included in the measurement of lease liabilities. • Lease assets obtained in exchange for lease liabilities totaled $29.6 million , offset by cancellation of leases that resulted in the reduction of lease assets obtained in exchange for leases liabilities which totaled $0.4 million . The weighted-average remaining lease term for operating leases was 7.2 years . The weight-average discount rate for operating leases was 4.22 percent as of June 30, 2019 . There were no material operating leases that we have entered into and that were yet to commence as of June 30, 2019 . The approximate aggregate commitments under non-cancelable operating leases in effect at June 30, 2019 and December 31, 2018 , were as follows (dollar amounts in thousands): June 30, December 31, 2019 $ 3,232 $ 5,646 2020 5,888 4,692 2021 4,954 3,864 2022 3,527 2,367 2023 3,038 2,162 Thereafter 11,668 10,296 Total lease payments $ 32,307 $ 29,027 Less: Imputed interest (1) 4,648 Present value of lease liabilities $ 27,659 (1) Calculated using our corporate borrowing rate based on the term of each lease ranging from 4.09 percent to 4.29 percent .

Income Taxes

Income Taxes	6 Months Ended
	Jun. 30, 2019
Income Tax Disclosure [Abstract]
Income Taxes	Income Taxes For the three months ended June 30, 2019 and 2018 , our provision for income taxes, as a percentage of income before income taxes was 45.7 percent and 116.4 percent , respectively, compared with a U.S. federal statutory rate of 21.0 percent. For the six months ended June 30, 2019 and 2018 , our provision for income taxes, as a percentage of income before income taxes was 43.9 percent and 86.5 percent , respectively, compared with a U.S. federal statutory rate of 21.0 percent. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2019 , was primarily attributed to current year foreign losses that presently do not provide future tax benefit, as well as net unfavorable foreign tax related items. The difference between the effective tax rate and the U.S. federal statutory tax rate for the three and six months ended June 30, 2018 , was primarily attributed to foreign losses during those periods, largely related to China, that were not expected to provide future tax benefit, as well as net unfavorable foreign tax related items. As the U.S. Department of the Treasury is working on finalizing Treasury Regulations with respect to the Tax Cuts and Jobs Act (Tax Reform Act), future changes could likewise affect recorded deferred tax assets and liabilities in later periods. Management is not aware of any such additional changes that would have a material effect on our results of operations, cash flows or financial position. Our U.S. federal income tax returns for 2015 through 2017 are open to examination for federal tax purposes. We have several foreign tax jurisdictions that have open tax years from 2012 through 2018. The Internal Revenue Service has notified us they will be conducting an audit of our U.S. federal income tax return for the 2017 tax year. As of June 30, 2019 and December 31, 2018 , we had accrued $2.2 million and $2.2 million , respectively, related to unrecognized tax positions. Interim income taxes are based on an estimated annualized effective tax rate applied to the respective quarterly periods, adjusted for discrete tax items in the period in which they occur. Although we believe our tax estimates are reasonable, we can make no assurance that the final tax outcome of these matters will not be different from that which we have reflected in our historical income tax provisions and accruals. Such differences could have a material impact on our income tax provision and operating results in the period in which we make such determination.

Commitments and Contingencies

Commitments and Contingencies	6 Months Ended
	Jun. 30, 2019
Commitments and Contingencies Disclosure [Abstract]
Commitments and Contingencies	Commitments and Contingencies Legal Proceedings We are party to various legal proceedings. Management cannot predict the ultimate outcome of these proceedings, individually or in the aggregate, or their resulting effect on our business, financial position, results of operations or cash flows as litigation and related matters are subject to inherent uncertainties, and unfavorable rulings could occur. Were an unfavorable outcome to occur, there exists the possibility of a material adverse impact on our business, financial position, results of operations, or cash flows for the period in which the ruling occurs and/or future periods. We maintain product liability, general liability and excess liability insurance coverage. However, no assurances can be given that such insurance will continue to be available at an acceptable cost to us, that such coverage will be sufficient to cover one or more large claims, or that the insurers will not successfully disclaim coverage as to a pending or future claim. Non-Income Tax Contingencies We have reserved for certain state sales and use tax and foreign non-income tax contingencies based on the likelihood of an obligation in accordance with accounting guidance for probable loss contingencies. Loss contingency provisions are recorded for probable losses at management’s best estimate of a loss, or when a best estimate cannot be made, a minimum loss contingency amount is recorded. We provide provisions for potential payments of tax to various tax authorities for contingencies related to non-income tax matters, including value-added taxes and sales tax. We provide provisions for U.S. state sales taxes in each of the states where we have nexus. At June 30, 2019 and December 31, 2018 , accrued liabilities were $0.3 million and $0.3 million , respectively, related to non-income tax contingencies. While we believe that the assumptions and estimates used to determine contingent liabilities are reasonable, the ultimate outcome of these matters cannot presently be determined. We believe future payments related to these matters could range from $0 to approximately $3.5 million . Other Litigation We are a party to various other legal proceedings in the United States and several foreign jurisdictions related to value-added tax assessments and other civil litigation. As of June 30, 2019 and December 31, 2018 , accrued liabilities were $2.0 million and $1.7 million , respectively, related to the estimated outcome of these proceedings. In addition, we are a party to other litigation where there is a reasonable possibility that a loss may be incurred, either the losses are not considered to be probable or we cannot at this time estimate the loss, if any; therefore, no provision for losses has been provided. We believe future payments related to these matters could range from $0 to approximately $0.4 million .

Related Party Transactions

Related Party Transactions	6 Months Ended
	Jun. 30, 2019
Related Party Transactions [Abstract]
Related Party Transactions	Related Party Transactions During the three and six months ended June 30, 2019 , NSP China did no t borrow any amounts from the Company or our joint venture partner. During the three and six months ended June 30, 2018 , NSP China borrowed $0 and $2.0 million from the Company and $0 and $0.5 million from our joint venture partner, respectively. These notes are payable in one year and bear interest of 3.0 percent . As of June 30, 2019 and December 31, 2018 outstanding borrowings by NSP China from the Company were $6.2 million and $6.0 million , respectively. As of June 30, 2019 and December 31, 2018 outstanding borrowings by NSP China from our joint venture partner were $1.5 million and $1.5 million , respectively. The notes between NSP China and the Company eliminate in consolidation.

Fair Value Measurements

Fair Value Measurements	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Fair Value Measurements	Fair Value Measurements The fair value of a financial instrument is the amount that could be received upon the sale of an asset or paid to transfer a liability in an orderly transaction between market participants at the measurement date. Financial assets are marked to bid prices and financial liabilities are marked to offer prices. Fair value measurements do not include transaction costs. A fair value hierarchy is used to prioritize the quality and reliability of the information used to determine fair values of each financial instrument. Categorization within the fair value hierarchy is based on the lowest level of input that is significant to the fair value measurement. The fair value hierarchy is defined into the following three categories: Level 1: Quoted market prices in active markets for identical assets or liabilities. Level 2: Observable market based inputs or unobservable inputs that are corroborated by market data. Level 3: Unobservable inputs that are not corroborated by market data. The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2019 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,432 $ — $ — $ 1,432 Total assets measured at fair value on a recurring basis $ 1,432 $ — $ — $ 1,432 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2018 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,308 $ — $ — $ 1,308 Total assets measured at fair value on a recurring basis $ 1,308 $ — $ — $ 1,308 Investment securities - trading — Our trading portfolio consists of various marketable securities that are valued using quoted prices in active markets. For the six months ended June 30, 2019 , and for the year ended December 31, 2018 , there were no fair value measurements using significant other observable inputs (Level 2) or significant unobservable inputs (Level 3). The carrying amounts reflected on the condensed consolidated balance sheets for cash and cash equivalents, accounts receivable, and accounts payable approximate fair value due to their short-term nature. The carrying amount reflected on the condensed consolidated balance sheets for the revolving credit facility approximates fair value due to it being variable-rate debt. During the six months ended June 30, 2019 and 2018 , we did not have any re-measurements of non-financial assets at fair value on a nonrecurring basis subsequent to their initial recognition.

Revenue Recognition

Revenue Recognition	6 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Revenue Recognition	Revenue Recognition Revenue Recognition Net sales include products and shipping and handling charges, net of estimates for product returns and any related sales incentives or rebates based upon historical information and current trends. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring products. All revenue is recognized when the Company satisfies its performance obligations under the contract. We recognize revenue by transferring the promised products to the customer, with revenue recognized at shipping point, the point in time the customer obtains control of the products. The majority of our contracts have a single performance obligation and are short term in nature. Contracts with multiple performance obligations are insignificant. Sales taxes and value added taxes in the United States and foreign jurisdictions that are collected from customers and remitted to governmental authorities are accounted for on a net basis and therefore are excluded from net sales. Amounts received for unshipped merchandise are recorded as deferred revenue. A reserve for product returns is recorded based upon historical experience and current trends. We allow independent Managers or Distributors to return the unused portion of products within ninety days of purchase if they are not satisfied with the product. In some of our markets, the requirements to return product are more restrictive. From time to time, our U.S. operations extend short-term credit associated with product promotions. In addition, for certain of our international operations, we offers credit terms consistent with industry standards within the country of operation. Volume incentives, and other sales incentives or rebates are a significant part of our direct sales marketing program, and represent commission payments made to independent distributors. These payments are designed to provide incentives for reaching higher sales levels. The amount of volume incentive expense recognized is determined based upon the amount of qualifying purchases in a given month and recorded as volume incentive expense. Payments to independent Managers and Distributors for sales incentives or rebates related to their own purchases are recorded as a reduction of revenue. Payments for sales incentives and rebates are calculated monthly based upon qualifying sales. Contract Liabilities - Customer Loyalty Programs We record contract liabilities for loyalty point programs in deferred revenue. These programs are accounted for as a reduction in the transaction price and are generally recognized as points that are redeemed for additional products. The following table presents changes in these contract liability balances for the six -month period ended June 30, 2019 (U.S. dollars in thousands): Outstanding at December 31, 2018 $ 1,079 Increase (decrease) attributed to: Customer loyalty net deferrals 3,041 Customer loyalty redemptions (3,011 ) Outstanding at June 30, 2019 $ 1,109 The table above excludes liability for sales returns, as they are insignificant. Disaggregation of Revenue Our products are grouped into six principal categories: general health, immune, cardiovascular, digestive, personal care and weight management. We have four business segments that are based primarily upon the geographic region where each segment operates. Each of the geographic segments operate under the Nature’s Sunshine Products and Synergy® WorldWide brands. See Note 7, Segment Information, for further information on our reportable segments and presentation of disaggregated revenue by reportable segment and product category. Practical Expedients and Exemptions We have made the accounting policy election to treat shipping and handling as a fulfillment activity rather than a promised service under Topic 606. We generally expense volume incentives when incurred because the amortization period would have been one year or less. All of our contracts with customers have a duration of less than one year . The value of any unsatisfied performance obligations is insignificant.

Basis of Presentation (Policies

Basis of Presentation (Policies)	6 Months Ended
	Jun. 30, 2019
Organization, Consolidation and Presentation of Financial Statements [Abstract]
Basis of Presentation	Basis of Presentation We are a natural health and wellness company primarily engaged in the manufacturing and direct selling of nutritional and personal care products. We are a Utah corporation with our principal place of business in Lehi, Utah, and sell our products to a sales force of independent distributors who uses the products themselves or resells them to consumers.
Principles of Consolidation	Principles of Consolidation The accompanying unaudited condensed consolidated financial statements have been prepared in accordance with generally accepted accounting principles for interim financial information and with the instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all of the information and footnotes required by generally accepted accounting principles for complete financial statements. The unaudited condensed consolidated financial statements include the accounts of the Company and its subsidiaries. All intercompany accounts and transactions are eliminated in consolidation. In the opinion of management, the accompanying unaudited condensed consolidated financial statements contain all adjustments (consisting of normal recurring accruals), considered necessary for a fair presentation of our financial information as of June 30, 2019 , and for the three and six -month periods ended June 30, 2019 and 2018 . The results of operations of any interim period are not necessarily indicative of the results of operations to be expected for the year ending December 31, 2019 . It is suggested that these condensed consolidated financial statements be read in conjunction with the consolidated financial statements and the notes thereto included in our Annual Report on Form 10-K for the year ended December 31, 2018 .
Noncontrolling Interests	Noncontrolling Interests Noncontrolling interests decreased as a result of the net loss attributable to the noncontrolling interests by $0.1 million and $0.3 million during the six months ended June 30, 2019 and 2018 , respectively. As of June 30, 2019 and December 31, 2018 , noncontrolling deficits were $25,000 and noncontrolling interests were $0.1 million , respectively.
Recent Accounting Pronouncements	Recent Accounting Pronouncements We adopted the requirements of Accounting Standards Update ("ASU") No. 2016-02, Leases (Topic 842): Accounting for Leases effective January 1, 2019. This update requires that lessees recognize right-of-use assets and lease liabilities that are measured at the present value of the future lease payments at lease commencement date. See Note 8 - Leases for additional disclosure of the adoption of Topic 842. In February 2018, the Financial Accounting Standards Board ("FASB") issued ASU 2018-02, Income Statement - Reporting Comprehensive Income (Topic 220): Reclassification of Certain Effects from Accumulated Other Comprehensive Income. This update allows a reclassification of stranded tax effects, resulting from the Tax Cuts and Jobs Act 2017, from accumulated other comprehensive income to retained earnings. This ASU is effective for annual periods beginning after December 15, 2018 with early adoption permitted. The adoption of ASU 2018-02 did not have a material effect on our results of operations, consolidated financial statements and footnote disclosures. In August 2018, the FASB issued ASU No. 2018-13, Fair Value Measurement (Topic 820): Disclosure Framework - Changes to the Disclosure Requirements for Fair Value Measurement. This ASU modifies the disclosure requirements on fair value measurements in Topic 820 based on the consideration of costs and benefits to promote the appropriate exercise and discretion by entities when considering fair value measurement disclosures and to clarify that materiality is an appropriate consideration of entities and their auditors when evaluating disclosure requirements. The amendments in this update are effective for reporting periods beginning after December 15, 2019, with early adoption permitted. We are evaluating the potential impact of this adoption on our consolidated financial statements.

Inventories (Tables)

Inventories (Tables)	6 Months Ended
	Jun. 30, 2019
Inventory Disclosure [Abstract]
Schedule of composition of inventories	The composition of inventories is as follows (dollar amounts in thousands): June 30, December 31, Raw materials $ 11,605 $ 10,410 Work in progress 1,286 1,524 Finished goods 31,037 30,114 Total inventories $ 43,928 $ 42,048

Net Income Per Share (Tables)

Net Income Per Share (Tables)	6 Months Ended
	Jun. 30, 2019
Earnings Per Share [Abstract]
Schedule of reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS	Following is a reconciliation of the numerator and denominator of Basic EPS to the numerator and denominator of Diluted EPS for the three and six months ended June 30, 2019 and 2018 (dollar and share amounts in thousands, except for per share information): Three Months Ended Six Months Ended 2019 2018 2019 2018 Net income attributable to common shareholders $ 2,689 $ 67 $ 4,446 $ 565 Basic weighted average shares outstanding 19,291 19,105 19,280 19,058 Basic earnings per share attributable to common shareholders $ 0.14 $ — $ 0.23 $ 0.03 Diluted shares outstanding: Basic weighted-average shares outstanding 19,291 19,105 19,280 19,058 Stock-based awards 311 297 316 350 Diluted weighted-average shares outstanding 19,602 19,402 19,596 19,408 Diluted earnings per share attributable to common shareholders $ 0.14 $ — $ 0.23 $ 0.03 Dilutive shares excluded from diluted-per-share amounts: Stock options 445 330 445 330 Anti-dilutive shares excluded from diluted-per-share amounts: Stock options 838 1,160 862 1,160

Capital Transactions (Tables)

Capital Transactions (Tables)	6 Months Ended
	Jun. 30, 2019
Equity [Abstract]
Schedule of stock option activity	Stock option activity for the six -month period ended June 30, 2019 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Exercise Price Per Share Options outstanding at December 31, 2018 1,114 $ 12.23 Granted — — Forfeited or canceled (173 ) 12.76 Exercised (1 ) 2.35 Options outstanding at June 30, 2019 940 12.15
Schedule of restricted stock unit activity	activity for the six -month period ended June 30, 2019 , is as follows (amounts in thousands, except per share information): Number of Shares Weighted Average Grant Date Fair Value Restricted Stock Units outstanding at December 31, 2018 1,058 $ 8.87 Granted 333 7.23 Forfeited (371 ) 9.92 Issued (109 ) 10.69 Restricted Stock Units outstanding at June 30, 2019 911 7.62

Segment Information (Tables)

Segment Information (Tables)	6 Months Ended
	Jun. 30, 2019
Segment Reporting [Abstract]
Schedule of reportable business segment information	Reportable business segment information is as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Net sales: Asia $ 35,162 $ 35,767 $ 68,758 $ 63,530 Europe 15,075 13,922 30,672 28,525 North America 34,620 35,518 71,143 73,623 Latin America and Other 5,867 6,059 11,423 12,930 Total net sales 90,724 91,266 181,996 178,608 Contribution margin (1): Asia 16,291 17,275 32,402 29,641 Europe 4,822 4,648 9,827 9,709 North America 12,026 11,180 25,418 24,592 Latin America and Other 2,418 2,393 4,740 4,821 Total contribution margin 35,557 35,496 72,387 68,763 Selling, general and administrative expenses (2) 31,019 33,310 64,871 65,696 Operating income 4,538 2,186 7,516 3,067 Other income (loss), net 306 (1,807 ) 258 (1,067 ) Income before provision for income taxes $ 4,844 $ 379 $ 7,774 $ 2,000 _________________________________________ (1) Contribution margin consists of net sales less cost of sales and volume incentives expense. (2) Service fees in China totaled $2.3 million and $4.5 million for the three and six -month periods ended June 30, 2019 , respectively, compared to $2.5 million and $4.0 million for the three and six -month periods ended June 30, 2018 . These service fees are included in selling, general and administrative expenses. Total assets per segment is set forth below (dollar amounts in thousands): June 30, December 31, Assets: Asia $ 72,752 $ 59,983 Europe 17,683 16,414 North America 117,182 109,091 Latin America and Other 8,634 7,528 Total assets $ 216,251 $ 193,016
Schedule of consolidated net sales revenue by geographical locations	From an individual country perspective, the United States and South Korea comprise 10 percent or more of consolidated net sales for the three and six -month periods ended June 30, 2019 and 2018 , as follows (dollar amounts in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Net sales: United States $ 32,194 $ 32,914 $ 66,155 $ 68,140 South Korea 18,923 19,608 37,451 34,192 Other 39,607 38,744 78,390 76,276 $ 90,724 $ 91,266 $ 181,996 $ 178,608
Schedule of revenue generated by each of the Company's product lines	Net sales generated by each of our product lines is set forth below (dollar amounts in thousands): Three Months Ended Six Months Ended 2019 2018 2019 2018 Asia General health $ 10,752 $ 8,519 $ 18,836 $ 14,753 Immune 199 133 357 434 Cardiovascular 11,561 13,496 23,394 23,398 Digestive 7,333 6,274 12,108 11,698 Personal care 1,820 3,086 6,087 5,268 Weight management 3,497 4,259 7,976 7,979 35,162 35,767 68,758 63,530 Europe General health $ 5,372 $ 5,424 $ 11,120 $ 10,928 Immune 1,090 832 2,363 1,776 Cardiovascular 2,766 2,806 5,617 5,863 Digestive 3,550 3,134 7,181 6,362 Personal care 1,661 1,048 3,160 2,211 Weight management 636 678 1,231 1,385 15,075 13,922 30,672 28,525 North America General health $ 14,934 $ 15,731 $ 30,682 $ 31,830 Immune 3,340 3,344 7,558 8,279 Cardiovascular 4,935 4,870 10,011 9,671 Digestive 8,523 8,521 17,244 17,497 Personal care 1,598 1,268 2,946 2,843 Weight management 1,290 1,784 2,702 3,503 34,620 35,518 71,143 73,623 Latin America and Other General health $ 1,783 $ 1,794 $ 3,395 $ 3,878 Immune 602 567 1,210 1,267 Cardiovascular 361 288 700 766 Digestive 2,645 2,931 5,181 5,883 Personal care 260 302 517 613 Weight management 216 177 420 523 5,867 6,059 11,423 12,930 $ 90,724 $ 91,266 $ 181,996 $ 178,608
Schedule of consolidated property, plant and equipment by geographical locations	From an individual country perspective, only the United States comprised 10 percent or more of consolidated property, plant and equipment as follows (dollar amounts in thousands): June 30, December 31, Property, plant and equipment: United States $ 57,608 $ 60,606 Other 4,303 3,455 Total property, plant and equipment $ 61,911 $ 64,061

Leases (Tables)

Leases (Tables)	6 Months Ended
	Jun. 30, 2019
Leases [Abstract]
Assets and liabilities, lease	Operating lease right-of-use assets and lease liabilities are as follows (dollar amounts in thousands): June 30, January 1, Assets: Operating lease right-of-use assets $ 26,361 $ 23,143 Liabilities: Current $ 5,241 $ 4,426 Long-term 22,418 19,566 Total operating lease liabilities $ 27,659 $ 23,992
Lessee, operating lease, liability, maturity	The approximate aggregate commitments under non-cancelable operating leases in effect at June 30, 2019 and December 31, 2018 , were as follows (dollar amounts in thousands): June 30, December 31, 2019 $ 3,232 $ 5,646 2020 5,888 4,692 2021 4,954 3,864 2022 3,527 2,367 2023 3,038 2,162 Thereafter 11,668 10,296 Total lease payments $ 32,307 $ 29,027 Less: Imputed interest (1) 4,648 Present value of lease liabilities $ 27,659 (1) Calculated using our corporate borrowing rate based on the term of each lease ranging from 4.09 percent to 4.29 percent .

Fair Value Measurements (Tables

Fair Value Measurements (Tables)	6 Months Ended
	Jun. 30, 2019
Fair Value Disclosures [Abstract]
Schedule of the Company's hierarchy for assets measured at fair value on a recurring basis	The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of June 30, 2019 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,432 $ — $ — $ 1,432 Total assets measured at fair value on a recurring basis $ 1,432 $ — $ — $ 1,432 The following table presents our hierarchy for our assets, measured at fair value on a recurring basis, as of December 31, 2018 (dollar amounts in thousands): Level 1 Level 2 Level 3 Quoted Prices in Active Markets for Identical Assets Significant Other Observable Inputs Significant Unobservable Inputs Total Investment securities - trading $ 1,308 $ — $ — $ 1,308 Total assets measured at fair value on a recurring basis $ 1,308 $ — $ — $ 1,308

Revenue Recognition (Tables)

Revenue Recognition (Tables)	6 Months Ended
	Jun. 30, 2019
Revenue from Contract with Customer [Abstract]
Contract with Customer, Asset and Liability	The following table presents changes in these contract liability balances for the six -month period ended June 30, 2019 (U.S. dollars in thousands): Outstanding at December 31, 2018 $ 1,079 Increase (decrease) attributed to: Customer loyalty net deferrals 3,041 Customer loyalty redemptions (3,011 ) Outstanding at June 30, 2019 $ 1,109 The table above excludes liability for sales returns, as they are insignificant.

Basis of Presentation (Details)

Basis of Presentation (Details) - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Noncontrolling Interest [Line Items]
Decrease in noncontrolling interest			$ 100,000	$ 300,000
Noncontrolling interest (deficit)	$ (25,000)		(25,000)		$ 63,000
Restructuring charges	400,000	$ 0	2,000,000	$ 0
Transition expenses	1,500,000		1,500,000
Accrued transition costs	600,000		600,000		1,000,000
Accrued Severance and Rent Costs
Noncontrolling Interest [Line Items]
Accrued severance and rent costs	$ 1,000,000		$ 1,000,000		$ 300,000

Inventories (Details)

Inventories (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Inventory Disclosure [Abstract]
Raw materials	$ 11,605	$ 10,410
Work in progress	1,286	1,524
Finished goods	31,037	30,114
Total inventories	$ 43,928	$ 42,048

Investment Securities - Tradi_2

Investment Securities - Trading (Details) - USD ($) $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Investments, Debt and Equity Securities [Abstract]
Trading securities portfolio	$ 1,432		$ 1,432		$ 1,308
Debt securities, trading, realized gain	$ 40	$ 34	$ 173	$ 11

Revolving Credit Facility (Deta

Revolving Credit Facility (Details) - Revolving credit facility - Bank of America Credit Agreement - USD ($)	Jul. 11, 2017	Jun. 30, 2019	Dec. 31, 2018
Long-term debt
Maximum borrowing capacity	$ 25,000,000
Annual commitment fee	0.20%
Long-term line of credit		$ 0
LIBOR
Long-term debt
Margin on variable rate	1.25%
Effective interest rate		3.65%	3.73%

Net Income Per Share (Details)

Net Income Per Share (Details) - USD ($) $ / shares in Units, shares in Thousands, $ in Thousands	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018
Earnings Per Share [Abstract]
Net income attributable to common shareholders	$ 2,689	$ 67	$ 4,446	$ 565
Basic weighted-average shares outstanding (in shares)	19,291	19,105	19,280	19,058
Basic earnings per share attributable to common shareholders (in dollars per share)	$ 0.14	$ 0	$ 0.23	$ 0.03
Diluted shares outstanding:
Basic weighted-average shares outstanding (in shares)	19,291	19,105	19,280	19,058
Stock-based awards (in shares)	311	297	316	350
Diluted weighted-average shares outstanding (in shares)	19,602	19,402	19,596	19,408
Diluted earnings per share attributable to common shareholders (in dollars per share)	$ 0.14	$ 0	$ 0.23	$ 0.03
Dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	445	330	445	330
Anti-dilutive shares excluded from diluted-per-share amounts:
Stock options (in shares)	838	1,160	862	1,160

Capital Transactions - Narrativ

Capital Transactions - Narrative (Details) - USD ($)	3 Months Ended		6 Months Ended		12 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2015	Dec. 31, 2018	Dec. 31, 2012
2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)							1,500,000
Additional number of shares authorized under the plan (in shares)					1,500,000
Maximum | 2009 Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Number of shares authorized under the plan (in shares)	400,000		400,000
Stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Options outstanding (in shares)	940,000		940,000			1,114,000
Aggregate intrinsic value, outstanding	$ 300,000		$ 300,000			$ 200,000
Exercised (in shares)			1,000	69,000
Exercised (in dollars per share)			$ 2.35	$ 5.11
Aggregate intrinsic values of options exercised			$ 10,000	$ 400,000
Tax benefit from the exercise of stock options			3,000	100,000
Time-based stock options
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 0	$ 100,000	$ 0	100,000
Time-based stock options | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			48 months
Performance based stock options operating income margins
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Operating income margin, one (as a percent)			6.00%
Operating income margin, two (as a percent)			8.00%
Operating income margin, three (as a percent)			10.00%
Unvested stock options outstanding (in shares)	0		0			0
Performance based stock options operating income margins | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period			1 year
Performance based stock options operating income margins | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period			1 year 3 months
RSUs
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Award performance period			3 years
Share-based compensation expense	$ 500,000	500,000	$ 600,000	$ 1,000,000
Discount for lack of marketability			13.40%
Expected volatility (as a percent)			50.00%
Unrecognized share-based compensation expense	$ 2,100,000		$ 2,100,000			$ 1,800,000
Weighted-average period over which the remaining compensation cost is expected to be recognized			11 months
Minimum withholding requirements (in shares)			23,000	40,000
RSUs | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Granted (in shares)			333,000
RSUs | Minimum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)			2.10%
RSUs | Minimum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			12 months
RSUs | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Risk-free interest rate (as a percent)			2.90%
RSUs | Maximum | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			36 months
RSUs | Director | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Restriction period for issuance of shares			2 years
Nonvested subject to restriction period (in shares)	78,000		78,000			80,000
Time-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years
Weighted-average grant date fair value (in dollars per share)			$ 8.59
Performance-Based Restricted Stock Units (RSUs)
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share-based compensation expense	$ 100,000	$ 0	$ 200,000	$ 0
Share based compensation potential compensation expense to be recognized	1,100,000		$ 1,100,000
Performance-Based Restricted Stock Units (RSUs) | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Weighted-average grant date fair value (in dollars per share)			$ 4.38
Performance-Based Restricted Stock Units (RSUs) | Maximum
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Share based compensation potential compensation expense to be recognized	$ 2,100,000		$ 2,100,000
Performance-Based Restricted Stock Units (RSUs) | Net Sales and Operating Income Targets | 2012 Stock Incentive Plan
Share-based Compensation Arrangement by Share-based Payment Award [Line Items]
Vesting period			3 years

Capital Transactions - Stock Op

Capital Transactions - Stock Option Activity (Details) - Stock options - $ / shares	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018
Number of Shares
Options outstanding at the beginning of the period (in shares)	1,114,000
Granted (in shares)	0
Forfeited or canceled (in shares)	(173,000)
Exercised (in shares)	(1,000)	(69,000)
Options outstanding at the end of the period (in shares)	940,000
Weighted Average Exercise Price Per Share
Options outstanding at the beginning of the period (in dollars per share)	$ 12.23
Granted (in dollars per share)	0
Forfeited or canceled (in dollars per share)	12.76
Exercised (in dollars per share)	2.35	$ 5.11
Options outstanding at the end of the period (in dollars per share)	$ 12.15

Capital Transactions - RSU Acti

Capital Transactions - RSU Activity (Details) - 2012 Stock Incentive Plan - RSUs	6 Months Ended
	Jun. 30, 2019$ / sharesshares
Number of Shares
Restricted Stock Units outstanding, beginning balance (in shares) | shares	1,058,000
Granted (in shares) | shares	333,000
Issued (in shares) | shares	(371,000)
Forfeited (in shares) | shares	(109,000)
Restricted Stock Units outstanding, ending balance (in shares) | shares	911,000
Weighted Average Grant Date Fair Value
Restricted Stock Units outstanding, beginning balance (in dollars per share) | $ / shares	$ 8.87
Granted (in dollars per share) | $ / shares	7.23
Issued (in dollars per share) | $ / shares	9.92
Forfeited (in dollars per share) | $ / shares	10.69
Restricted Stock Units outstanding, ending balance (in dollars per share) | $ / shares	$ 7.62

Segment Information (Details)

Segment Information (Details) $ in Thousands	3 Months Ended			6 Months Ended
	Jun. 30, 2019USD ($)segment	Mar. 31, 2019segment	Jun. 30, 2018USD ($)	Jun. 30, 2019USD ($)segment	Jun. 30, 2018USD ($)	Dec. 31, 2018USD ($)
Segment information
Number of business segments | segment	4			4
Net sales:
Total net sales revenue	$ 90,724		$ 91,266	$ 181,996	$ 178,608
Contribution margin:
Total contribution margin	35,557		35,496	72,387	68,763
Selling, general and administrative expenses	31,019		33,310	64,871	65,696
Operating income	4,538		2,186	7,516	3,067
Other income (loss), net	306		(1,807)	258	(1,067)
Income before provision for income taxes	4,844		379	7,774	2,000
Total property, plant and equipment	61,911			61,911		$ 64,061
Total assets	216,251			216,251		193,016
NSP Americas; NSP Russia, Central and Eastern Europe; and NSP China
Segment information
Number of operating segments | segment		3
Synergy WorldWide
Segment information
Number of operating segments | segment		1
Asia
Net sales:
Total net sales revenue	35,162		35,767	68,758	63,530
Contribution margin:
Total contribution margin	16,291		17,275	32,402	29,641
Total assets	72,752			72,752		59,983
Asia | General health
Net sales:
Total net sales revenue	10,752		8,519	18,836	14,753
Asia | Immune
Net sales:
Total net sales revenue	199		133	357	434
Asia | Cardiovascular
Net sales:
Total net sales revenue	11,561		13,496	23,394	23,398
Asia | Digestive
Net sales:
Total net sales revenue	7,333		6,274	12,108	11,698
Asia | Personal care
Net sales:
Total net sales revenue	1,820		3,086	6,087	5,268
Asia | Weight management
Net sales:
Total net sales revenue	3,497		4,259	7,976	7,979
Europe
Net sales:
Total net sales revenue	15,075		13,922	30,672	28,525
Contribution margin:
Total contribution margin	4,822		4,648	9,827	9,709
Total assets	17,683			17,683		16,414
Europe | General health
Net sales:
Total net sales revenue	5,372		5,424	11,120	10,928
Europe | Immune
Net sales:
Total net sales revenue	1,090		832	2,363	1,776
Europe | Cardiovascular
Net sales:
Total net sales revenue	2,766		2,806	5,617	5,863
Europe | Digestive
Net sales:
Total net sales revenue	3,550		3,134	7,181	6,362
Europe | Personal care
Net sales:
Total net sales revenue	1,661		1,048	3,160	2,211
Europe | Weight management
Net sales:
Total net sales revenue	636		678	1,231	1,385
North America
Net sales:
Total net sales revenue	34,620		35,518	71,143	73,623
Contribution margin:
Total contribution margin	12,026		11,180	25,418	24,592
Total assets	117,182			117,182		109,091
North America | General health
Net sales:
Total net sales revenue	14,934		15,731	30,682	31,830
North America | Immune
Net sales:
Total net sales revenue	3,340		3,344	7,558	8,279
North America | Cardiovascular
Net sales:
Total net sales revenue	4,935		4,870	10,011	9,671
North America | Digestive
Net sales:
Total net sales revenue	8,523		8,521	17,244	17,497
North America | Personal care
Net sales:
Total net sales revenue	1,598		1,268	2,946	2,843
North America | Weight management
Net sales:
Total net sales revenue	1,290		1,784	2,702	3,503
Latin America and Other
Net sales:
Total net sales revenue	5,867		6,059	11,423	12,930
Contribution margin:
Total contribution margin	2,418		2,393	4,740	4,821
Total assets	8,634			8,634		7,528
Latin America and Other | General health
Net sales:
Total net sales revenue	1,783		1,794	3,395	3,878
Latin America and Other | Immune
Net sales:
Total net sales revenue	602		567	1,210	1,267
Latin America and Other | Cardiovascular
Net sales:
Total net sales revenue	361		288	700	766
Latin America and Other | Digestive
Net sales:
Total net sales revenue	2,645		2,931	5,181	5,883
Latin America and Other | Personal care
Net sales:
Total net sales revenue	260		302	517	613
Latin America and Other | Weight management
Net sales:
Total net sales revenue	216		177	420	523
CHINA
Contribution margin:
Selling, general and administrative expenses	2,300		2,500	4,500	4,000
United States
Net sales:
Total net sales revenue	32,194		32,914	66,155	68,140
Contribution margin:
Total property, plant and equipment	57,608			57,608		60,606
South Korea
Net sales:
Total net sales revenue	18,923		19,608	37,451	34,192
Other
Net sales:
Total net sales revenue	39,607		$ 38,744	78,390	$ 76,276
Other
Contribution margin:
Total property, plant and equipment	$ 4,303			$ 4,303		$ 3,455

Leases - Narrative (Details)

Leases - Narrative (Details) - USD ($) $ in Thousands	3 Months Ended	6 Months Ended
	Jun. 30, 2019	Jun. 30, 2019	Jan. 01, 2019
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets	$ 26,361	$ 26,361
Operating lease, liability	27,659	27,659
Operating lease cost	1,700	3,400
Short-term lease cost	$ 45	100
Operating cash flows from operating leases		2,900
Leased assets obtained in exchange for operating lease liabilities		29,600
Reduction in lease assets obtained in exchange for lease liabilities		$ 400
Weighted-average remaining lease term (years)	7 years 2 months 19 days	7 years 2 months 19 days
Weighted-average discount rate	4.22%	4.22%
Accounting Standards Update 2016-02
New Accounting Pronouncements or Change in Accounting Principle [Line Items]
Operating lease right-of-use assets			$ 23,143
Operating lease, liability			$ 23,992

Leases - Assets and Liabilities

Leases - Assets and Liabilities (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Jan. 01, 2019
Assets:
Operating lease right-of-use assets	$ 26,361
Liabilities:
Current	5,241
Long-term	22,418
Total operating lease liabilities	$ 27,659
Accounting Standards Update 2016-02
Assets:
Operating lease right-of-use assets		$ 23,143
Liabilities:
Current		4,426
Long-term		19,566
Total operating lease liabilities		$ 23,992

Leases - Commitments Under Non-

Leases - Commitments Under Non-Cancelable Operating Leases (Details) - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Operating Leases, After Adoption of 842
2019	$ 3,232
2020	5,888
2021	4,954
2022	3,527
2023	3,038
Thereafter	11,668
Total lease payments	32,307
Less: Imputed interest	4,648
Present value of lease liabilities	$ 27,659
Operating Leases, Before Adoption of 842
2019		$ 5,646
2020		4,692
2021		3,864
2022		2,367
2023		2,162
Thereafter		10,296
Total lease payments		$ 29,027
Weighted-average discount rate	4.22%
Minimum
Operating Leases, Before Adoption of 842
Weighted-average discount rate	4.09%
Maximum
Operating Leases, Before Adoption of 842
Weighted-average discount rate	4.29%

Income Taxes (Details)

Income Taxes (Details) - USD ($) $ in Millions	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Income Tax Disclosure [Abstract]
Provision (benefit) for income taxes, as a percentage of income before income taxes	45.70%	116.40%	43.90%	86.50%
Liability related to unrecognized tax benefits	$ 2.2		$ 2.2		$ 2.2

Commitments and Contingencies (

Commitments and Contingencies (Details)	6 Months Ended
	Jun. 30, 2019USD ($)claim	Dec. 31, 2018USD ($)
Value-added tax assessments and other civil litigation
Commitments and contingencies
Minimum number of claims that the Company's insurance coverage may not be sufficient to cover | claim	1
Provision for losses	$ 0
Non-Income Tax Contingencies
Commitments and contingencies
Accrued liabilities	300,000	$ 300,000
Minimum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	0
Minimum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	0
Maximum | Value-added tax assessments and other civil litigation
Commitments and contingencies
Estimate of possible loss	400,000
Maximum | Non-Income Tax Contingencies
Commitments and contingencies
Estimate of possible loss	3,500,000
Pending Litigation
Commitments and contingencies
Accrued liabilities	$ 2,000,000	$ 1,700,000

Related Party Transactions (Det

Related Party Transactions (Details) - NSP China - Subsidiaries - USD ($)	3 Months Ended		6 Months Ended
	Jun. 30, 2019	Jun. 30, 2018	Jun. 30, 2019	Jun. 30, 2018	Dec. 31, 2018
Related Party Transaction [Line Items]
Notes receivable, related parties, current	$ 6,200,000		$ 6,200,000		$ 6,000,000
Company's Joint Venture Partner
Related Party Transaction [Line Items]
Notes receivable, related parties, current	1,500,000		1,500,000		$ 1,500,000
Notes Receivable
Related Party Transaction [Line Items]
Related party transaction, amount	0	$ 0	$ 0	$ 2,000,000
Related party transaction, rate			3.00%
Notes Receivable | Company's Joint Venture Partner
Related Party Transaction [Line Items]
Related party transaction, amount	$ 0	$ 0	$ 0	$ 500,000

Fair Value Measurements (Detail

Fair Value Measurements (Details) - Recurring basis - USD ($) $ in Thousands	Jun. 30, 2019	Dec. 31, 2018
Total
Fair value
Investment securities - trading	$ 1,432	$ 1,308
Total assets measured at fair value on a recurring basis	1,432	1,308
Level 1 - Quoted Prices in Active Markets for Identical Assets
Fair value
Investment securities - trading	1,432	1,308
Total assets measured at fair value on a recurring basis	1,432	1,308
Level 2 - Significant Other Observable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	0	0
Level 3 - Significant Unobservable Inputs
Fair value
Investment securities - trading	0	0
Total assets measured at fair value on a recurring basis	$ 0	$ 0

Revenue Recognition - Narrative

Revenue Recognition - Narrative (Details)	3 Months Ended	6 Months Ended
	Jun. 30, 2019segment	Jun. 30, 2019segmentproduct_category
Disaggregation of Revenue [Line Items]
Refund period		90 days
Number of principal categories of products | product_category		6
Number of business segments | segment	4	4
Maximum
Disaggregation of Revenue [Line Items]
Contract with customer, contract term		1 year

Revenue Recognition - Changes i

Revenue Recognition - Changes in Contract Liabilities (Details) $ in Thousands	6 Months Ended
	Jun. 30, 2019USD ($)
Change in Contract with Customer, Liability [Roll Forward]
Outstanding at December 31, 2018	$ 1,079
Increase (decrease) attributed to:
Customer loyalty net deferrals	3,041
Customer loyalty redemptions	(3,011)
Outstanding at June 30, 2019	$ 1,109